Home Current Issue Previous Issues Published Ahead-of-Print Collections Blog For Authors Journal Info
Skip Navigation LinksHome > November 2012 - Volume 50 - Issue 11 > Active Surveillance of Postmarket Medical Product Safety in...
Medical Care:
doi: 10.1097/MLR.0b013e31826c874d
Original Articles

Active Surveillance of Postmarket Medical Product Safety in the Federal Partners' Collaboration

Robb, Melissa A. BSN*; Racoosin, Judith A. MD, MPH*; Worrall, Chris BS; Chapman, Summer BSc; Coster, Trinka MD, MS§; Cunningham, Francesca E. PharmD

Collapse Box

Abstract

After half a century of monitoring voluntary reports of medical product adverse events, the Food and Drug Administration (FDA) has launched a long-term project to build an adverse events monitoring system, the Sentinel System, which can access and evaluate electronic health care data to help monitor the safety of regulated medical products once they are marketed. On the basis of experience gathered through a number of collaborative efforts, the Federal Partners’ Collaboration pilot project, involving FDA, the Centers for Medicare & Medicaid Services, the Department of Veteran Affairs, and the Department of Defense, is already enabling FDA to leverage the power of large public health care databases to assess, in near real time, the utility of analytical tools and methodologies that are being developed for use in the Sentinel System. Active medical product safety surveillance is enhanced by use of these large public health databases because specific populations of exposed patients can be identified and analyzed, and can be further stratified by key variables such as age, sex, race, socioeconomic status, and basis for eligibility to examine important subgroups.

© 2012 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.